MXPA03011499A - Proteinas de fusion de fce para el tratamiento de alergia y asma. - Google Patents

Proteinas de fusion de fce para el tratamiento de alergia y asma.

Info

Publication number
MXPA03011499A
MXPA03011499A MXPA03011499A MXPA03011499A MXPA03011499A MX PA03011499 A MXPA03011499 A MX PA03011499A MX PA03011499 A MXPA03011499 A MX PA03011499A MX PA03011499 A MXPA03011499 A MX PA03011499A MX PA03011499 A MXPA03011499 A MX PA03011499A
Authority
MX
Mexico
Prior art keywords
epsilon
gamma
treatment
fragment
fce
Prior art date
Application number
MXPA03011499A
Other languages
English (en)
Inventor
An Ling-Ling
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of MXPA03011499A publication Critical patent/MXPA03011499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invencion incluye fragmentos de Fce conjugados con fragmentos de Fcy, por ejemplo Fce1-Bisagra- Fce2-Fce3Fce4-Fcy; Bisagra-Fce2-Fce3-Fce4-Fcy; Fce2-Fce3-Fce4- Fcy; Fce2-Fce3-Fcy; Fce3-Fcy; y Fce3-Fce4-Fcy, o cualquier derivado o peptido, que tiene una funcion inmunologica equivalente. El fragmento Fcy puede ser un fragmento de cualquiera de las subclaces de IgG (IgG1, IgG2, IgG3 o IgG4), preferentemente IgGl o IgG3, en donde el fragmento se une a FcyRIIB. La presente invencion tambien incluye composiciones adecuadas para su administracion a un paciente que sufre de una enfermedad alergica, que comprende el constructo de la proteina de fusion en una composicion farmaceutica que incluye, por ejemplo, un excipiente, diluente o portador. Este tratamiento se puede combinar con terapia anti-IgE o inmunoterapia de alergeno.
MXPA03011499A 2001-06-15 2002-06-14 Proteinas de fusion de fce para el tratamiento de alergia y asma. MXPA03011499A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29871001P 2001-06-15 2001-06-15
PCT/US2002/019448 WO2002102320A2 (en) 2001-06-15 2002-06-14 Fce fusion proteins for treatment of allergy and asthma

Publications (1)

Publication Number Publication Date
MXPA03011499A true MXPA03011499A (es) 2004-04-05

Family

ID=23151696

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011499A MXPA03011499A (es) 2001-06-15 2002-06-14 Proteinas de fusion de fce para el tratamiento de alergia y asma.

Country Status (7)

Country Link
US (1) US20040198961A1 (es)
EP (1) EP1478748A4 (es)
JP (1) JP2004537991A (es)
CN (1) CN1541266A (es)
CA (1) CA2455387A1 (es)
MX (1) MXPA03011499A (es)
WO (1) WO2002102320A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
AU2002254753C1 (en) * 2001-05-01 2008-09-18 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
CN1317304C (zh) * 2004-03-10 2007-05-23 伍祥贵 一种融合蛋白及其编码基因与表达方法和应用
EP1781269A2 (en) * 2004-05-20 2007-05-09 St. Mary's Hospital NHS Trust IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1956985A2 (en) * 2005-11-23 2008-08-20 Universität Zürich Allergy treatment by epicutaneous allergen administration
AU2009288289B2 (en) * 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
CN101633698B (zh) * 2009-08-26 2011-12-21 北京精益泰翔技术发展有限公司 一种免疫融合蛋白及其编码基因与应用
WO2012169741A2 (ko) * 2011-06-07 2012-12-13 (주)네오팜 ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
EP3017048A4 (en) * 2013-07-01 2017-05-17 University of Maryland, College Park Fc coupled compositions and methods of their use
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
CN110551705A (zh) * 2019-09-18 2019-12-10 重庆医科大学 肺炎链球菌蛋白PepN在抗过敏性哮喘中的应用
WO2022039547A1 (ko) * 2020-08-21 2022-02-24 아주대학교산학협력단 감마 불변부위(cγ1)와 엡실론 불변부위(cε2-4)가 융합된 중쇄와 경쇄의 불변부위로 이루어진 항체 단편 및 이의 용도
CN116410327A (zh) * 2021-12-31 2023-07-11 祝道成 一种融合蛋白及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6280994B1 (en) * 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
AU2002254753C1 (en) * 2001-05-01 2008-09-18 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases

Also Published As

Publication number Publication date
JP2004537991A (ja) 2004-12-24
EP1478748A2 (en) 2004-11-24
US20040198961A1 (en) 2004-10-07
EP1478748A4 (en) 2005-09-21
WO2002102320A2 (en) 2002-12-27
CA2455387A1 (en) 2002-12-27
WO2002102320A3 (en) 2004-08-26
CN1541266A (zh) 2004-10-27

Similar Documents

Publication Publication Date Title
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
US8337844B2 (en) CD20-binding polypeptide compositions for treating autoimmune disease
RU2764031C2 (ru) Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью
Pichler Adverse side‐effects to biological agents
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
ATE454124T1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
EP2325209A3 (en) Improved protofibril selective antibodies and the use thereof
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
WO2004066932A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
CA2618681A1 (en) Identification and engineering of antibodies with variant fc regions and methods of using same
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
DE60032486D1 (de) Prion protein peptide und deren verwendung
MXPA01008612A (es) Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
Brezski et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs
CN112839716A (zh) 组织蛋白酶s抑制剂在抵抗抗药物抗体形成中的用途
AU4104700A (en) Antibody and chemokine constructs that are directed to CCR5, and their use for treating autoimmune diseases
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
MXPA01008613A (es) Epitopos o mimotopos derivados del dominio c-epsilon-2 de ige, antagonistas de los mismos y sus usos terapeuticos.
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO1998054209A3 (en) Human mast cell function-associated antigen (mafa) and uses thereof
WO2023144423A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof